← FDA DRUG APPROVALS

FDA ANDA · ANDA076056

PRAVASTATIN SODIUM

Sponsor: AUROBINDO PHARMA USA

APPLICATION
ANDA076056
TYPE
ANDA
ORIGINAL APPROVAL
2006-04-24
LATEST ACTION
2025-02-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 20MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 40MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 10MG · TABLET · ORAL

Approval history

2025-02-24Labeling · Supplement 25 · standardAP
2021-02-16Labeling · Supplement 21 · standardAP
2017-01-23Labeling · Supplement 16 · standardAP
2015-11-30Labeling · Supplement 14 · standardAP
2013-02-05Labeling · Supplement 13 · standardAP
2012-12-30Labeling · Supplement 12 · standardAP
2012-05-04Labeling · Supplement 11AP
2011-09-27Labeling · Supplement 10AP
2010-01-08Manufacturing (CMC) · Supplement 8AP
2007-10-05Labeling · Supplement 7AP
2007-03-16Labeling · Supplement 5AP
2006-09-27Labeling · Supplement 2AP
2006-04-24OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →